Empirical/Statistical Studies

Bibliographic References tagged with Empirical/Statistical Studies

Not finding what you're looking for? Try using Advanced Search.
Not finding what you're looking for? Try using Advanced Search.
Carpenter D, Bowers J, Grimmer J, Moffitt S, Nall C, Zucker EJ. Deadline Effects in Regulatory Review: A Methodological and Empirical Analysis. 2007.
Carpenter D, Bowers J, Grimmer J, Moffitt S, Nall C, Zucker EJ. Deadline Effects in Regulatory Review: A Methodological and Empirical Analysis. 2007.
Carpenter D, Feinstein B, Moore C, Turenne M, Yohai I, Zucker EJ. Why Do Bigger Firms Receive Faster Drug Approvals? 2004.
Carpenter D, Feinstein B, Moore C, Turenne M, Yohai I, Zucker EJ. Why Do Bigger Firms Receive Faster Drug Approvals? 2004.
Carpenter D, Chattopadhyay J, Moffitt S, Nall C. The Complications of Controlling Agency Time Discretion: FDA Deadlines and Postmarket Drug Safety. American Journal of Political Science. 2012.
Carpenter D, Chattopadhyay J, Moffitt S, Nall C. The Complications of Controlling Agency Time Discretion: FDA Deadlines and Postmarket Drug Safety. American Journal of Political Science. 2012.
Carpenter D, Moffitt S, Moore C, Rynbrandt R, Ting M, Yohai I, Zucker EJ. Early-Entrant Protection in Approval Regulation: Theory and Evidence from FDA Drug Review. Journal of Law Economics and Organization . 2010;26(2).
Carpenter D, Moffitt S, Moore C, Rynbrandt R, Ting M, Yohai I, Zucker EJ. Early-Entrant Protection in Approval Regulation: Theory and Evidence from FDA Drug Review. Journal of Law Economics and Organization . 2010;26(2).
Carpenter D, Zucker EJ, Avorn J. Drug Review Deadlines and Subsequent Safety Problems. New England Journal of Medicine . 2008;358(13):1354–61.
Carpenter D, Zucker EJ, Avorn J. Drug Review Deadlines and Subsequent Safety Problems. New England Journal of Medicine . 2008;358(13):1354–61.
Carpenter D. Groups the Media Agency Waiting Costs and FDA Drug Approval. American Journal of Political Science. 2002;46(2):490–505.
Carpenter D. Groups the Media Agency Waiting Costs and FDA Drug Approval. American Journal of Political Science. 2002;46(2):490–505.